That's not an advocacy position — it's the official determination of the U.S. Department of Health and Human Services and the White House. Federal agencies have formally found that cannabis treats recognized medical conditions and carries less abuse potential than substances currently in Schedule I or II. This page presents those findings alongside the clinical evidence that supports them.
The federal government's own expert agencies — HHS, FDA, NIDA, and the White House — have each made formal, official determinations that cannabis has accepted medical use and a lower potential for abuse than substances currently in Schedule I or II. These are not advocacy positions. They are the conclusions of scientific reviews conducted under the Controlled Substances Act's own procedures.
In August 2023, the U.S. Department of Health and Human Services completed a full scientific and medical evaluation of cannabis under the CSA's eight-factor test and transmitted a formal recommendation to the DEA to move cannabis from Schedule I to Schedule III. The recommendation explicitly concluded that cannabis "has a currently accepted medical use in treatment in the United States" and "has a potential for abuse less than the drugs or other substances in Schedules I and II." This was the first time HHS had ever made such a recommendation for cannabis. HHS announcement, August 2023 ↗
As part of the HHS review, FDA's Center for Drug Evaluation and Research evaluated clinical evidence and found credible scientific support for cannabis in the treatment of chronic pain, anorexia related to certain medical conditions (including HIV/AIDS wasting), and chemotherapy-induced nausea and vomiting. This was not a novel finding — FDA approved Marinol (dronabinol, Schedule III) for chemotherapy nausea in 1985 and for HIV wasting in 1992, and approved Epidiolex (cannabidiol) for severe pediatric epilepsy in 2018. These approvals establish that cannabinoids have recognized therapeutic value within FDA's own drug framework.
NIDA — the federal agency specifically responsible for assessing drug abuse potential — formally concurred with FDA's recommendation that cannabis be rescheduled from Schedule I to Schedule III. In April 2024, the DEA proposed that rescheduling in the Federal Register ↗. NIDA's concurrence directly contradicts the Schedule I classification's claim that cannabis has "a high potential for abuse" with "no accepted safety."
President Trump's December 2025 executive order documented that more than 30,000 licensed healthcare practitioners across 43 U.S. jurisdictions are authorized to recommend medical cannabis to more than 6 million registered patients for at least 15 medical conditions. The order acknowledged that the HHS recommendation was based in part on FDA's finding of credible scientific support for cannabis in treating pain, anorexia, and chemotherapy-induced nausea. White House EO, December 18, 2025 ↗
The National Academies' comprehensive 2017 review — the most rigorous independent evaluation of the evidence base — concluded that there is substantial or conclusive evidence that cannabis is effective for chronic pain in adults, muscle spasticity associated with multiple sclerosis, and chemotherapy-induced nausea and vomiting. The report reviewed more than 10,000 scientific abstracts and rated the evidence for these conditions at the highest level of certainty used in clinical evidence reviews. National Academies report ↗
One of the most consistent findings in the cannabis medical literature is that access to medical cannabis leads to meaningful reductions in opioid prescribing and use. In the context of the U.S. opioid epidemic — which kills approximately 80,000 Americans per year — this effect has major public health implications.
The evidence comes from multiple independent lines of research. The landmark 2016 Bradford & Bradford study examined Medicare Part D prescription data across all medical cannabis states from 2010 to 2015 and found that when medical dispensaries opened, there were 3.742 million fewer daily opioid doses prescribed per year — a reduction of approximately 1,826 doses per year per physician. A broader 2024 analysis published in PLOS ONE found an average 16% reduction in opioid prescriptions in states with medical cannabis programs, controlling for demographics and other confounders. The effect was most pronounced for neuropathic pain, cancer pain, and chronic musculoskeletal pain.
These findings align with patient-reported data: multiple surveys of medical cannabis patients show that 40–60% report substituting cannabis for opioids, with most preferring cannabis due to lower perceived risks and better quality of life.
Veterans with PTSD are among the most common users of medical cannabis for symptom management, yet VA physicians are currently prohibited from recommending it despite 43 states authorizing it. A 2023 DAV report cited this as a documented policy gap. Veterans are disproportionately affected by both chronic pain and opioid use disorder — two conditions where the substitution evidence is most consistent.
The theory that cannabis use inevitably leads to harder drugs has been used to justify Schedule I classification for decades. Federal agencies — including the DEA, HHS, and CDC — have each reviewed this claim and found it unsupported by the evidence.
Under Factor 8 of the CSA's eight-factor scheduling test, the DEA is required to evaluate whether a substance is a "precursor" to another controlled substance. The DEA's own analysis — published in the Federal Register in 2016 — explicitly concluded: "Marijuana is not an immediate precursor of another controlled substance." This is the DEA's formal legal finding, not an advocacy claim.
HHS concluded in its 2023 scheduling review that "although many individuals with a drug abuse disorder may have used marijuana as one of their first illicit drugs, this does not mean that individuals initiated with marijuana inherently will go on to become regular users of other illicit drugs." HHS further found that common gateway studies are methodologically flawed, typically measuring "any use of an illicit drug" rather than clinical diagnostic criteria for substance abuse or dependence. The CDC states directly: "Most people who use marijuana do not go on to use other, 'harder' drugs."
The gateway hypothesis has been tested extensively in longitudinal studies. The consistent finding is that while cannabis use sometimes precedes other drug use, order of initiation does not establish cause. The strongest predictors of drug dependence are socioeconomic factors, trauma history, family history of substance use, and pre-existing mental health conditions — not cannabis use itself. A landmark World Health Organization analysis of 17 countries found that the order of drug use initiation varies by country based on drug availability, not pharmacology — in countries where cannabis is less prevalent, other substances are often initiated first. This cross-national variation is incompatible with a causal gateway model.
State-level legalization of cannabis for adult use has consistently not led to increased use of other illicit drugs among adults. A 2019 analysis cited in the HHS rescheduling commentary found that legalizing recreational cannabis did not increase substance use disorders or use of other illicit drugs and may reduce alcohol-related problems in some populations. HHS has twice formally determined — in its 2023 rescheduling recommendation and in prior scheduling reviews — that cannabis is not a precursor of any other controlled substance.